Opening Recap
Market Pulse: Shipping and biotech headlines rip through markets after FedEx crushed volume expectations and niche therapies won key approvals, putting logistics and healthcare squarely in focus.
Key Movers: FedEx’s volume surge, Merck’s Keytruda Qlex green light, and Replimune’s 39% slide punched trading rooms with headline-driven volatility.
Macro & Politics: The FDA accelerated Orland Park’s Barth Syndrome therapy and Medtronic’s Altaviva device, while Pfizer’s public spat with President Trump reminded everyone political turf wars can spook investors.
What’s Next: Watch early shipping data and looming FDA decisions on melanoma and immuno-oncology therapies—those catalysts could redraw sector playbooks before midday.
Market Commentary
📈 Breaking Financial News
FedEx (NYSE:FDX) Sees Large Volume Increase After Earnings Beat
FedEx Corporation (NYSE:FDX – Get Free Report) shares saw an uptick in trading volume on Friday following a stronger than expected earnings report. 3,126,218 shares were traded during mid-day trading, an increase of 57% from the previous session’s volume of 1…
Merck announces FDA approval of Keytruda Qlex
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday.
Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece aft…
Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the best performers on Thursday. Replimune…
Medtronic receives FDA approval for Altaviva device
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
🔍 Market Analysis & Insights
Closing Bell Movers: FedEx jumps over 5% after earnings beat
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
5 Reasons Pfizer’s Reply to President Trump Is Complete Rubbish
On September 1, 2025, on Truth Social, President Trump posted a demand for transparency. Specifically, he called for public release of the data he has received from pharmaceutical companies regarding the modified-mRNA-based Covid injections, calling out Pfize…
Orland Park baby's treatment for rare genetic disease Barth Syndrome granted accelerated approval by Food and Drug Administration
A baby in the Chicago area is battling a rare disease and desperately needs a drug treatment for a better life. The drug has now been granted accelerated approval by the FDA.
Edwards Lifesciences Corporation (EW): A Bull Case Theory
We came across a bullish thesis on Edwards Lifesciences Corporation on Natan’s Substack. In this article, we will summarize the bulls’ thesis on EW. Edwards …
Scotiabank Lifts Telus International (TIXT) Price Target on TELUS Digital Merger Plans
Telus International (NYSE:TIXT) is one of the best AI stocks to buy under $5. On September 4, Scotiabank raised the stock’s price target to $4.50 from $3.50….
The TRUTH About Trump and Musk?
If you think there's something strange about the “feud” between Trump and Musk… You need to see THIS jaw-dropping video… Because it explains what could REALLY be going on behind the scenes… And how it could hand investors a stake in a $12 trillion revolution.
💰 Investment Opportunities
H&R Block, Inc. (HRB): A Bull Case Theory
We came across a bullish thesis on H&R Block, Inc. on X.com by FishtownCap. In this article, we will summarize the bulls’ thesis on HRB. H&R Block, Inc.’s…
A Looming FDA Decision, Approval Odds, Investor Takeaways
For investors, SRRK stock offers a high-probability FDA catalyst, meaningful upside in SMA, and additional optionality in obesity and more.
What are presidential hopeful Gareth Sheridan’s business partner’s links with Russia?
Moldovan investors own bulk of Sheridan’s Nutriband business, US filings show
Hollywood Teamsters Condemn Kimmel Shutdown as ‘Greed-Fueled Consolidation of Corporate Power’
“Corporations are selling out working families and our American freedoms to amass even greater wealth,” the union says. The post Hollywood Teamsters Condemn Kimmel Shutdown as ‘Greed-Fueled Consolidation of Corporate Power’ appeared first on TheWrap.
Wegovy Pill Matches Shot for Weight Loss in Clinical Trial
Novo Nordisk's pill version of Wegovy could be just as effective as the injectable shot, according to new clinical trial data released by the company. In the study, overweight or obese adults took the daily oral medication as prescribed lost an average of 16.…
The Real Reason 218,000 Acres Just Vanished
The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake. Find out why this could be the most lucrative “underground” energy story in America.
Everyone’s ignoring the real test behind FedEx’s volume spike reported by ETF Daily News: if global e-commerce demand flags, that rally will be a short-lived sugar high. Meanwhile, Replimune’s 39% crash in “Nosedives 39% as FDA Approval for Melanoma Treatment ‘Uncertain’” on Biztoc.com shows regulators can yank approvals at a whim, exposing biotech names to seismic sell-offs. Under that cloud, even strong logistics names could get dragged back to earth.
It’s damn wild how political landmines link disparate sectors: Pfizer’s public takedown of President Trump in “5 Reasons Pfizer’s Reply to President Trump Is Complete Rubbish” on Activistpost.com slams home that pharma CEOs are dancing on thin ice, and Gareth Sheridan’s Russia-tied partner laid out in The Irish Times’ “What are presidential hopeful Gareth Sheridan’s business partner’s links with Russia?” underlines how one subpoena threat can blow up entire industries. That political blowback is fueling headline risk across healthcare and beyond, and few are paying attention.
Here’s the drill: trim biotech positions to headline-hawk mode and size them like you’re navigating a minefield, while sticking to logistics names with real volume muscle—ETF Daily News’s FedEx story looks safer than some penny biotechs, but set stops. Monitor telecom consolidation in “Scotiabank Lifts Telus International (TIXT) Price Target on TELUS Digital Merger Plans” from Yahoo Entertainment, because that stealth M&A wave could catch traders flat-footed. If you’re not jittery by these catalysts, you’re carrying more risk than you should.